Andre, you still invested? We've survived wave one down, at least I hope we've hit support and you are still standing. We'll see what surprises follow next week with China, or oil. You saw the pr on AUPH, and the upcoming conference call. Any clues? I may add more shares Tuesday, but wanted to know your read on the situation. The PR sounded good! I suspect this week's drop was manipulation to shake the tree, or just the market. As to MRNS, I've now upped my stake, average just over $6. It's a great stock. Might also buy some TRVN now, you still like? As far as I can tell, these have great promise. Also CLDX at $7!
Ha! I am in MRNS, AVXL, CLDX as of today. Been looking at FOMX. Check out AUPH, conference call update next week on their trial, see PR and sock spike from last week. Low float, low volume. Good luck!
Thanks MGM. Ranger says a dormant stock is a good stock, we are both dormant and overlooked from the volume and price action. Time to add before the excitement returns, and it will. I already have enough, so this is for others I say this. Good weekend all!
Exactly, remember Franklin and others who bought the offering paid $6.00 per share back in November. The market took us down after the run to $8.00 but the chart indicates we've now got the trend change back up. Also, using the multiple of 11.2 times our market cap to that of SAGE, our share price is discounted already by that substantial difference, and Ganaxolone would appear to be the superior medication. Let's see, if we were to be trading at parity with SAGE, our share price would be $50 right now. No wonder Franklin is buying hand over fist.
Christopher Michael Cashman, MARINUS PHARMACEUTICALS INC's President and CEO and a director of the company, recently acquired 28,245 shares of the company. The buys took place at prices ranging from $1.04 to $5.61 per share, on dates ranging from November 06 to February 09, 2016. Cashman now owns 140,769 shares of the company. Cashman operates out of Radnor, PA.
Of further note: The low of today was a new all time low at $4.00 intra-day but the stock rallied .53 to close UP for a change at $4.53, a gain of over 5%. YAY! I managed to buy another 500 shares at $4.28 so my average is now just over $6.00 on 7,500 shares.
A few other tidbits:
The all time closing high was August 4th $19.58, and they did the offering in November, closing on the raise of just under $30MM at $6 a share, 5MM shares.
The chart is looking much better tonight after we got a white candle, let's hope it has reversed the trend! Slow stoch has turned up, should have a bullish cross tomorrow. RSI has turned up with a reading of 31.08. Our market cap is now $87.59 MM. Comparing that to SAGE at 981,67MM, for a multiple of 11.2 times our market cap. They did an offering at $47.50 the second week of January which closed on January 12th. Those investors are looking at the $30.66 price today and wishing they had bought MRNS instead for $4.53!
On January 12, 2016, Sage Therapeutics, Inc. (the "Company"), completed the sale of 3,157,894 shares of its common stock to the underwriters as part of the Company's previously announced public offering at the public offering price of $47.50 per share, less underwriting discounts and commissions (the "Closing"). The Company's proceeds raised in the offering, after underwriting discounts and before estimated expenses of the offering, were approximately $141.0 million. In addition, SAGE has granted the underwriters a 30-day option to purchase up to an additional 473,684 shares of its common stock.
Here's to a good rest of February! GLAL
Dr. Missling has been consistently clear about his intention to present data at an upcoming science conference, that is one reason to wait, another is the meltdown of stocks in today's market. Wait for the calm, hope it coincides with the conference of choice. On website today: 33rd Camerino-Cyprus Symposium May 15-19, 2016?
Or, my --as yet unconfirmed-- speculation: 14th AAT Conference, March 9 - 12, Athens, Greece.
Soflaturtle, do you like the recovery prospects of LCI better than HZNP? Thinking of switching horses. And, DEPO has practically caught up with HZNP, did you notice?
All of a sudden it shot up to 74.4 with bids over 2 cents lower, maybe shorts are getting smart and covering before news hits and takes this up multiples of its trading value today?
Both in MRNS and the S&P and other indexes, at least for this leg down. Yellen is nuts, she needs to be replaced. Rattling the markets when she didn't need to, with all her wanderings, exploring negative interest rates, can you imagine?
So, the sponsor of the study is UC Davis, not SAGE? "Who is the researcher in question?" I added some more shares today in all this craziness. 4.28 500 shares.
CTAD was in Barcelona Spain in December, and yes, traveling to an International Alzheimer's Conference to announce 'State of the Art' data on the top world health problem not having effective treatment options--it's all important and where it is matters not.
I'd like to see this post, please reprint it here so I don't have to look for it, thanks.
It has been suggested that Dr. Abraham Fisher is from Israel, and they are naming him as a place holder for Dr. Missling because the Company is playing this close to the vest at this time so as to keep it under wraps longer.
On Anavex-273 "I would like to point out one thing, which is I would say, that the last month was the most relevant information that we saw with Anavex-273 a very strong dose response curve in two independent cognitive markers, and we will share that data in a detailed way in a forthcoming scientific conference."
Now, taking that further search on the web for the site for "International Athens/Springfield Symposium on Advances in Alzheimer Therapy, 2016
Under the tab Professional Sources, go to the drop down "Conference Calendar" and under the date 09 – 12 March 2016, at 10:40-11:00 you will find a listing for a speaker "TBA" speaking on the subject 'State of the Art lecture' with subject matter
10:40 – 11:00 State of the art lecture
tba (Ness Ziona, Israel)
A unique target for a comprehensive therapy of Alzheimer’s disease: concomitant
activation of SIGMA/M1 muscarinic receptors.
This hasn't been announced by the Company and is a guess that this could be when Christopher makes the data available. Good luck longs.
Sentiment: Strong Buy
Hope to see the old gal fade more and more, but Bernie, can't the Dem's do better than Bernie? Donald was presidential tonight.
So much risk, in going long biotech stocks this last 7-8 months. May-July was the exit with portfolio at highs. After that it went from the gradual downtrend to the big drops in Augusr and September, and now 2016. The next rally, when it happens, will be time to heal and re-evaluate staying invested. Fragile X had better not disappoint!
The downtrend in SAGE ended today with the stock rallying almost 5%, but it didn't seem to help MRNS down 3.44%. I added to my position today, hope she catches a good wind soon.
With the ratio now 6.6 as adjusted to the (now) price today MRNS 4.49, SAGE 30, the ratio times our share price gives us $30 per share. Come on Fragile X, that would start the uptick!
That gap has narrowed since you posted this to 6.33. Sage 29.77, Mrns 4.70. Now 6.33. Sage dropped fast after they did their secondary at 47.50 which they reported as closed on Jan 12th.